12
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Demographic characteristics, clinical and laboratory features, and the distribution of pathogenic variants in the CFTR gene in the Cypriot cystic fibrosis (CF) population demonstrate the utility of a national CF patient registry

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Specialized clinical care for cystic fibrosis (CF) in Cyprus, a small island country, has been implemented since the 1990s. However, only recently, a national CF patient registry has been established for the systematic recording of patients’ data. In this study, we aim to present data on the epidemiological, genotypic and phenotypic features of CF patients in the country from the most recent data collection in 2019, with particular emphasis on notable rare or unique cases.

          Results

          Overall, data from 52 patients are presented, 5 of whom have deceased and 13 have been lost to follow-up in previous years. The mean age at diagnosis was 7.2 ± 12.3 years, and the mean age of 34 alive patients by the end of 2019 was 22.6 ± 13.2 years. Patients most commonly presented at diagnosis with acute or persistent respiratory symptoms (46.2%), failure to thrive or malnutrition (40.4%), and dehydration or electrolyte imbalance (32.7%). Sweat chloride levels were diagnostic (above 60 mmol/L) in 81.8% of examined patients. The most common identified mutation was p.Phe508del (F508del) (45.2%), followed by p.Leu346Pro (L346P) (6.7%), a mutation detected solely in individuals of Cypriot descent. The mean BMI and FEV 1 z-scores were 0.2 ± 1.3 and − 2.1 ± 1.7 across all age groups, respectively, whereas chronic Pseudomonas aeruginosa colonization was noted in 26.9% of patients. The majority of patients (74.5%) were eligible to receive at least one of the available CFTR modulator therapies. In 25% of patients we recovered rare or unique genotypic profiles, including the endemic p.Leu346Pro (L346P), the rare CFTR-dup2, the co-segregated c.4200_4201delTG/c.489 + 3A > G, and the polymorphism p.Ser877Ala.

          Conclusions

          CF patient registries are particularly important in small or isolated populations, such as in Cyprus, with rare or unique disease cases. Their operation is necessary for the optimization of clinical care provided to CF patients, enabling their majority to benefit from evolving advances in precision medicine.

          Supplementary Information

          The online version contains supplementary material available at 10.1186/s13023-021-02049-z.

          Related collections

          Most cited references43

          • Record: found
          • Abstract: found
          • Article: not found

          Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele

          Cystic fibrosis is caused by mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR) protein, and nearly 90% of patients have at least one copy of the Phe508del CFTR mutation. In a phase 2 trial involving patients who were heterozygous for the Phe508del CFTR mutation and a minimal-function mutation (Phe508del-minimal function genotype), the next-generation CFTR corrector elexacaftor, in combination with tezacaftor and ivacaftor, improved Phe508del CFTR function and clinical outcomes.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.

            Increasing the activity of defective cystic fibrosis transmembrane conductance regulator (CFTR) protein is a potential treatment for cystic fibrosis. We conducted a randomized, double-blind, placebo-controlled trial to evaluate ivacaftor (VX-770), a CFTR potentiator, in subjects 12 years of age or older with cystic fibrosis and at least one G551D-CFTR mutation. Subjects were randomly assigned to receive 150 mg of ivacaftor every 12 hours (84 subjects, of whom 83 received at least one dose) or placebo (83, of whom 78 received at least one dose) for 48 weeks. The primary end point was the estimated mean change from baseline through week 24 in the percent of predicted forced expiratory volume in 1 second (FEV(1)). The change from baseline through week 24 in the percent of predicted FEV(1) was greater by 10.6 percentage points in the ivacaftor group than in the placebo group (P<0.001). Effects on pulmonary function were noted by 2 weeks, and a significant treatment effect was maintained through week 48. Subjects receiving ivacaftor were 55% less likely to have a pulmonary exacerbation than were patients receiving placebo, through week 48 (P<0.001). In addition, through week 48, subjects in the ivacaftor group scored 8.6 points higher than did subjects in the placebo group on the respiratory-symptoms domain of the Cystic Fibrosis Questionnaire-revised instrument (a 100-point scale, with higher numbers indicating a lower effect of symptoms on the patient's quality of life) (P<0.001). By 48 weeks, patients treated with ivacaftor had gained, on average, 2.7 kg more weight than had patients receiving placebo (P<0.001). The change from baseline through week 48 in the concentration of sweat chloride, a measure of CFTR activity, with ivacaftor as compared with placebo was -48.1 mmol per liter (P<0.001). The incidence of adverse events was similar with ivacaftor and placebo, with a lower proportion of serious adverse events with ivacaftor than with placebo (24% vs. 42%). Ivacaftor was associated with improvements in lung function at 2 weeks that were sustained through 48 weeks. Substantial improvements were also observed in the risk of pulmonary exacerbations, patient-reported respiratory symptoms, weight, and concentration of sweat chloride. (Funded by Vertex Pharmaceuticals and others; VX08-770-102 ClinicalTrials.gov number, NCT00909532.).
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.

              Cystic fibrosis is a life-limiting disease that is caused by defective or deficient cystic fibrosis transmembrane conductance regulator (CFTR) protein activity. Phe508del is the most common CFTR mutation.
                Bookmark

                Author and article information

                Contributors
                yiallouros.panayiotis@ucy.ac.cy
                matthaiou.andreas@ucy.ac.cy
                anagnostopoulou.pinelopi@ucy.ac.cy
                kouis.panayiotis@ucy.ac.cy
                malgorzata.libik@fnmotol.cz
                tadamide@yahoo.gr
                adonisele@gmail.com
                demetrioua@gmail.com
                phiv.ioannou@gmail.com
                gtanteles@cing.ac.cy
                harry@cing.ac.cy
                pavlosf@cing.ac.cy
                milan.macek.jr@lfmotol.cuni.cz
                vassosn@cing.ac.cy
                laphylac@cing.ac.cy
                Journal
                Orphanet J Rare Dis
                Orphanet J Rare Dis
                Orphanet Journal of Rare Diseases
                BioMed Central (London )
                1750-1172
                2 October 2021
                2 October 2021
                2021
                : 16
                : 409
                Affiliations
                [1 ]GRID grid.6603.3, ISNI 0000000121167908, Respiratory Physiology Laboratory, Medical School, Shacolas Educational Centre for Clinical Medicine, , University of Cyprus, ; 215/6 Palaios Dromos Lefkosias Lemesou, 2029 Aglantzia, Nicosia, Cyprus
                [2 ]Paediatric Pulmonology Unit, Hospital ‘Archbishop Makarios III’, Nicosia, Cyprus
                [3 ]GRID grid.416192.9, ISNI 0000 0004 0644 3582, Pulmonology Clinic, , Nicosia General Hospital, ; Nicosia, Cyprus
                [4 ]GRID grid.460767.4, ISNI 0000 0004 0474 1308, Pulmonology Clinic, , Paphos General Hospital, ; Paphos, Cyprus
                [5 ]Private Practice, Nicosia, Cyprus
                [6 ]GRID grid.417705.0, ISNI 0000 0004 0609 0940, Department of Molecular Genetics, Function and Therapy, , The Cyprus Institute of Neurology and Genetics, ; Nicosia, Cyprus
                [7 ]GRID grid.417705.0, ISNI 0000 0004 0609 0940, Cyprus School of Molecular Medicine, , The Cyprus Institute of Neurology and Genetics, ; Nicosia, Cyprus
                [8 ]GRID grid.417705.0, ISNI 0000 0004 0609 0940, Department of Clinical Genetics, , The Cyprus Institute of Neurology and Genetics, ; Nicosia, Cyprus
                [9 ]GRID grid.4491.8, ISNI 0000 0004 1937 116X, Department of Biology and Medical Genetics, 2nd Faculty of Medicine and Motol University Hospital, , Charles University, ; Prague, Czechia
                Author information
                http://orcid.org/0000-0002-8339-9285
                Article
                2049
                10.1186/s13023-021-02049-z
                8487500
                34600583
                a6754b98-71d3-488c-9d71-318764fbf286
                © The Author(s) 2021

                Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

                History
                : 6 April 2021
                : 19 September 2021
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/501100004117, A.G. Leventis Foundation;
                Funded by: FundRef http://dx.doi.org/10.13039/100011022, Vertex Pharmaceuticals;
                Award ID: CG-2015-1046430
                Funded by: Czech Ministry of Health
                Award ID: IP00064203/6003
                Award Recipient :
                Funded by: Czech Ministry of Youth, Education and Sports
                Award ID: LM2018132
                Award ID: CZ.02.1.01/0.0/0.0/18_046/0015515
                Award Recipient :
                Categories
                Research
                Custom metadata
                © The Author(s) 2021

                Infectious disease & Microbiology
                cftr gene,cftr modulators,cystic fibrosis,next-generation sequencing,patient registry

                Comments

                Comment on this article